Coya Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Coya Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.95M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $3.55M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $6.00M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 19, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.23M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($14.88M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($7.99M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($12.24M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($4.89M) | Mar 29, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.56M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($17.25M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($7.90M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($9.81M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($4.87M) | Mar 29, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.74M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($10.29M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($11.19M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($7.24M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($3.90M) | Mar 29, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.95M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $44.35M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $41.26M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $8.40M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $4.79M | Mar 29, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.92M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $4.77M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $5.63M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $16.79M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $1.15M | Mar 29, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.03M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $39.58M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $35.64M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($8.39M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $3.64M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $8.30M | Mar 29, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($61.96M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($40.74M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($25.86M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($17.87M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($5.62M) | Mar 29, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.82M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $38.34M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $32.63M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $5.93M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $4.34M | Mar 29, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 29, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.93M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 16.71M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 14.41M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 2.59M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 2.59M | Mar 29, 2023 |